Benzinga | Nov 1, 2021 07:35AM EDT

Wedbush Initiates Coverage On Theseus Pharmaceuticals with Outperform Rating, Announces Price Target of $24

Wedbush analyst David Nierengarten initiates coverage on Theseus Pharmaceuticals (NASDAQ:THRX) with a Outperform rating and announces Price Target of $24.